Genzyme’s Allston facility was decontaminated in June.
(Wendy Maeda/Globe Staff/File 2009)
Genzyme is facing FDA fines
Allston plant to get increased oversight
Genzyme’s Allston facility was decontaminated in June.
(Wendy Maeda/Globe Staff/File 2009)
Federal regulators are preparing to fine Genzyme Corp. and step up supervision of the company’s troubled Allston drug manufacturing plant after a string of embarrassing quality problems at the facility. (Full article: 816 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
